Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITACITINIB in Non Severe HLH
NCT05063110Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of itacitinib in hemophagocytic lymphohistiocytosis (HLH), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2022; status: completed.
02
Drugs
itacitinib
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT05063110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063110.